ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

PYXS Pyxis Oncology Inc

4.40
-0.01 (-0.23%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Pyxis Oncology Inc NASDAQ:PYXS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.01 -0.23% 4.40 4.40 4.70 4.78 4.29 4.50 818,440 01:00:00

Pyxis Oncology to Participate in Fireside Chat at BofA Securities 2022 Healthcare Conference

27/04/2022 11:35am

GlobeNewswire Inc.


Pyxis Oncology (NASDAQ:PYXS)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Pyxis Oncology Charts.

Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today announced that Lara Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 2:40 p.m. PT in Las Vegas, Nevada.

A webcast of the fireside chat can be accessed on the Investors section of the Pyxis Oncology website at ir.pyxisoncology.com. Following the live event, a replay of the webcast will be archived for up to 90 days.

About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a multi-asset multi-modality company focused on defeating difficult to treat cancers and improve patient lives. By leveraging our fully integrated research, development and commercial capabilities, our expert team is efficiently building a diversified portfolio of next-generation therapeutics. Pyxis Oncology’s therapeutic candidates are designed to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis Oncology has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies. To learn more about Pyxis Oncology visit www.pyxisoncology.com.

Pyxis Oncology Contact:Courtney DuganVice President, Head of Investor Relations & Corporate Communications(617) 500-8872

1 Year Pyxis Oncology Chart

1 Year Pyxis Oncology Chart

1 Month Pyxis Oncology Chart

1 Month Pyxis Oncology Chart

Your Recent History

Delayed Upgrade Clock